Article Text

Download PDFPDF
Original article
Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction
  1. Supriya Shore1,
  2. Philip G Jones2,
  3. Thomas M Maddox3,4,
  4. Steven M Bradley3,4,
  5. Joshua M Stolker5,
  6. Suzanne V Arnold2,6,
  7. Susmita Parashar1,
  8. Pamela Peterson4,7,
  9. Deepak L Bhatt8,
  10. John Spertus2,6,
  11. P Michael Ho3,4
  1. 1Emory University School of Medicine, Atlanta, Georgia, USA
  2. 2Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA
  3. 3Veterans Affairs Eastern Colorado Health Care System, Denver, Colorado, USA
  4. 4University of Colorado—School of Medicine, Aurora, Colorado, USA
  5. 5Saint Louis University, St Louis, Missouri, USA
  6. 6University of Missouri-Kansas City, Kansas City, Missouri, USA
  7. 7Denver Health Medical Center, Denver, Colorado, USA
  8. 8Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
  1. Correspondence to Dr Supriya Shore, Division of Cardiology, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle, WMB 308, Atlanta, GA 30322, USA; supriyashore{at}


Background Prior studies have demonstrated that patients with high-risk acute myocardial infarction (AMI) are less likely to receive guideline-directed medications during hospitalisation. It is unknown if this paradox persists following discharge. We aimed to assess if persistence with guideline-directed medications post discharge varies by patients’ risk following AMI.

Methods Data were analysed from two prospective, multicentre US AMI registries. The primary outcome was persistence with all prescribed guideline-directed medications (aspirin, β-blockers, statins, angiotensin-antagonists) at 1, 6 and 12 months post discharge. The association between risk and medication persistence post discharge was assessed using multivariable mixed-effect models.

Results Among 6434 patients with AMI discharged home, 2824 were considered low-risk, 2014 intermediate-risk and 1596 high-risk for death based upon their Global Registry of Acute Coronary Event (GRACE) 6-month risk score. High-risk was associated with a lower likelihood of receiving all appropriate therapies at discharge compared with low-risk patients (relative risk (RR) 0.90; 95% CI 0.87 to 0.94). At 12 months, the rate of persistence with all prescribed therapies was 61.5%, 57.9% and 45.9% among low-risk, intermediate-risk and high-risk patients, respectively. After multivariable adjustment, high-risk was associated with lower persistence with all prescribed medications (RR 0.87; 95% CI 0.82 to 0.92) over follow-up. Similar associations were seen for individual medications. Over the 5 years of the study, persistence with prescribed therapies post discharge improved modestly among high-risk patients (RR 1.05; 95% CI 1.03 to 1.08 per year).

Conclusions High-risk patients with AMI have a lower likelihood of persistently taking prescribed medications post discharge as compared with low-risk patients. Continued efforts are needed to improve the use of guideline-directed medications in high-risk patients.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.